Insulin degludec/insulin aspart: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
== | {{Short description|Combination insulin medication}} | ||
[[Insulin degludec]] | {{Infobox drug | ||
| name = Insulin degludec/insulin aspart | |||
| type = combo | |||
| image = <!-- Image removed --> | |||
| caption = <!-- Caption removed --> | |||
| component1 = [[Insulin degludec]] | |||
| class1 = [[Long-acting insulin]] | |||
| component2 = [[Insulin aspart]] | |||
| class2 = [[Rapid-acting insulin]] | |||
| tradename = Ryzodeg | |||
| routes_of_administration = [[Subcutaneous injection]] | |||
| atc_prefix = A10 | |||
| atc_suffix = AE06 | |||
| legal_status = Rx-only | |||
| pregnancy_category = C | |||
| cas_number = 1260291-89-5 | |||
| drugbank = DB06655 | |||
| kegg = D10310 | |||
}} | |||
'''Insulin degludec/insulin aspart''' is a [[combination medication]] used in the management of [[diabetes mellitus]]. It is a mixture of two types of insulin: [[insulin degludec]], a [[long-acting insulin]], and [[insulin aspart]], a [[rapid-acting insulin]]. This combination is marketed under the brand name '''Ryzodeg'''. | |||
Insulin degludec/insulin aspart is used | |||
== | ==Medical uses== | ||
Insulin degludec/insulin aspart is indicated for the treatment of [[type 1 diabetes]] and [[type 2 diabetes]] in adults. It helps to control [[blood glucose levels]] by providing both basal and prandial insulin coverage. | |||
== | ==Mechanism of action== | ||
The combination of insulin degludec and insulin aspart works by mimicking the body's natural pattern of insulin release. [[Insulin degludec]] provides a steady, long-lasting insulin level, while [[insulin aspart]] offers a rapid onset of action to manage blood sugar spikes after meals. | |||
== | ==Administration== | ||
The medication is administered via [[subcutaneous injection]]. The dosing schedule is typically individualized based on the patient's needs, blood glucose monitoring results, and glycemic control goals. | |||
[[ | ==Side effects== | ||
[[ | Common side effects include [[hypoglycemia]], [[allergic reactions]], and [[injection site reactions]]. Patients should be monitored for signs of low blood sugar and other adverse effects. | ||
==See | ==See also== | ||
* [[Insulin therapy]] | * [[Insulin therapy]] | ||
* [[Diabetes management]] | * [[Diabetes management]] | ||
* [[Hypoglycemia]] | |||
[[Category: | ==References== | ||
[[Category:Insulin]] | {{Reflist}} | ||
[[Category: | |||
==External links== | |||
* [https://www.wikimd.com/wiki/Insulin_degludec/insulin_aspart Insulin degludec/insulin aspart on WikiMD] | |||
[[Category:Combination drugs]] | |||
[[Category:Insulin therapies]] | |||
[[Category:Diabetes treatments]] | |||
Latest revision as of 04:37, 29 December 2024
Combination insulin medication
| Insulin degludec/insulin aspart | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | Subcutaneous injection |
| Pregnancy category | C |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | Rx-only |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Insulin degludec/insulin aspart is a combination medication used in the management of diabetes mellitus. It is a mixture of two types of insulin: insulin degludec, a long-acting insulin, and insulin aspart, a rapid-acting insulin. This combination is marketed under the brand name Ryzodeg.
Medical uses[edit]
Insulin degludec/insulin aspart is indicated for the treatment of type 1 diabetes and type 2 diabetes in adults. It helps to control blood glucose levels by providing both basal and prandial insulin coverage.
Mechanism of action[edit]
The combination of insulin degludec and insulin aspart works by mimicking the body's natural pattern of insulin release. Insulin degludec provides a steady, long-lasting insulin level, while insulin aspart offers a rapid onset of action to manage blood sugar spikes after meals.
Administration[edit]
The medication is administered via subcutaneous injection. The dosing schedule is typically individualized based on the patient's needs, blood glucose monitoring results, and glycemic control goals.
Side effects[edit]
Common side effects include hypoglycemia, allergic reactions, and injection site reactions. Patients should be monitored for signs of low blood sugar and other adverse effects.
See also[edit]
References[edit]
<references group="" responsive="1"></references>